MedImmune, Inc. Promotes Smullen To Senior Vice President, Sales

GAITHERSBURG, Md., Feb. 27 /PRNewswire-FirstCall/ -- MedImmune, Inc. today announced that it has promoted R. Michael Smullen to senior vice president, sales. In his new role, Mike will assume additional responsibilities for sales operations, trade and distribution, managed care and national accounts, and sales training. He will continue to oversee the infectious disease sales team.

"Over the 12 years that I have worked with Mike, I have greatly valued his ability to identify, recruit and train outstanding sales professionals and to motivate them to achieve results that would not be attainable without his leadership," said David M. Mott, chief executive officer and president. "Over his tenure at the company, he has brought a clear and consistent vision for how to build and manage a biotechnology sales organization and he has consistently embraced and inspired our entrepreneurial culture.

"I look forward to working with Mike and his team to take our sales organization to the next level as we build a truly world class sales organization," Mott continued. "Together, we will be working to bring better tools, training and support to our sales professionals, while maintaining our historical commitment to an entrepreneurial and accountable sales culture. We will also be working to increase our customer focus at the highest levels of the organization and to enhancing cross functional collaboration to ensure that we bring the full resources of MedImmune to bear for our patients and customers."

Since joining MedImmune in 1994 as vice president, sales, Mr. Smullen has been responsible for building the company's sales organization from its original 14 representatives to what will be more than 400 professionals following the completion of the company's current expansion. Annual sales have grown from $35 million in 1994 to more than $1 billion in the United States. During this time, Mr. Smullen and his sales team successfully launched the first monoclonal antibody approved in the U.S. for an infectious disease, Synagis(R) (palivizumab), which has become the ninth most successful biotech product of all time surpassing $1 billion in annual sales in 2005.

Prior to joining MedImmune, Mr. Smullen served as national sales director for Synergen, Inc., a biopharmaceutical company, where he was responsible for developing the strategic plan and design for Synergen's first U.S.-based sales force. Prior to Synergen, Mr. Smullen held the position of national sales director for Fujisawa U.S.A. He was responsible for building Fujisawa'a first U.S.-based sales force, and also helped to establish its first managed care group. Mr. Smullen started his professional career in 1976 as a sales representative at Boehringer Ingelheim, and spent several years at SmithKline Beecham in sales, sales training and sales management. Mr. Smullen holds a bachelor's degree from Norwich University, Northfield, VT.

About MedImmune, Inc.

MedImmune strives to provide better medicines to patients, new medical options for physicians, rewarding careers to employees, and increased value to shareholders. Dedicated to advancing science and medicine to help people live better lives, the company is focused on the areas of infectious disease, cancer and inflammatory diseases. With more than 2,000 employees worldwide, MedImmune is headquartered in Maryland. For more information, visit the company's website at http://www.medimmune.com.

CONTACT: Investors: Peter Vozzo, +1-301-398-4358 or Media: ClarenciaStephen, +1-301-398-4073, both of MedImmune, Inc.

Web site: http://www.medimmune.com//